Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Small-cell lung cancer, drawn from the whole corpus: 431 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to Small-cell lung cancer itself. Grouped by the type that holds them; each list opens that type's own page.
Extensive-stage disease almost always relapses after first-line therapy, so maintenance (lurbinectedin-atezolizumab, tarlatamab) is the current lever; median survival is still barely over a year.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
No validated predictive biomarker for immunotherapy benefit; PD-L1 and TMB do not work in SCLC.
Sequencing of tarlatamab, I-DXd, lurbinectedin, and platinum rechallenge is untested.
Cytokine release syndrome and neurotoxicity of T-cell engagers require inpatient step-up dosing that many community centres cannot provide.
Background: Immune-related adverse events (irAEs). Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Prophylactic cranial irradiation versus MRI surveillance remains unresolved until SWOG S1827 reads out.
Transformed SCLC arising from EGFR-mutant NSCLC has no dedicated evidence base.
Screening rarely catches SCLC early; prevention is tobacco control.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Trials rarely enrol patients with poor performance status, who are common in this disease.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 95 changes by month →When this page itself was last checked or edited.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Unresectable stage III EGFR mutation-positive non-small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Concurrent cisplatin-etoposide with thoracic radiotherapy (45 Gy twice daily or 60-70 Gy once daily), then durvalumab consolidation up to 2 years (ADRIATIC); PCI or MRI surveillance. (NCCN 1 (durvalumab consolidation, category 1), ESMO-MCBS A)